These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

218 related items for PubMed ID: 12670352

  • 1. Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients.
    Mourad FH, Hoffbrand AV, Sheikh-Taha M, Koussa S, Khoriaty AI, Taher A.
    Br J Haematol; 2003 Apr; 121(1):187-9. PubMed ID: 12670352
    [Abstract] [Full Text] [Related]

  • 2. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
    Daar S, Pathare AV.
    Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
    [Abstract] [Full Text] [Related]

  • 3. Oral deferiprone for iron chelation in people with thalassaemia.
    Fisher SA, Brunskill SJ, Doree C, Chowdhury O, Gooding S, Roberts DJ.
    Cochrane Database Syst Rev; 2013 Aug 21; (8):CD004839. PubMed ID: 23966105
    [Abstract] [Full Text] [Related]

  • 4. Combined therapy with deferiprone and desferrioxamine.
    Wonke B, Wright C, Hoffbrand AV.
    Br J Haematol; 1998 Nov 21; 103(2):361-4. PubMed ID: 9827905
    [Abstract] [Full Text] [Related]

  • 5. Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients.
    Taher A, Sheikh-Taha M, Koussa S, Inati A, Neeman R, Mourad F.
    Eur J Haematol; 2001 Jul 21; 67(1):30-4. PubMed ID: 11553264
    [Abstract] [Full Text] [Related]

  • 6. Therapeutic mechanism of combined oral chelation therapy to maximize efficacy of iron removal in transfusion-dependent thalassemia major - a pilot study.
    Lin CH, Chen X, Wu CC, Wu KH, Song TS, Weng TF, Hsieh YW, Peng CT.
    Expert Rev Hematol; 2019 Apr 21; 12(4):265-272. PubMed ID: 30920854
    [Abstract] [Full Text] [Related]

  • 7. Timed non-transferrin bound iron determinations probe the origin of chelatable iron pools during deferiprone regimens and predict chelation response.
    Aydinok Y, Evans P, Manz CY, Porter JB.
    Haematologica; 2012 Jun 21; 97(6):835-41. PubMed ID: 22180427
    [Abstract] [Full Text] [Related]

  • 8. The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study.
    Totadri S, Bansal D, Bhatia P, Attri SV, Trehan A, Marwaha RK.
    Pediatr Blood Cancer; 2015 Sep 21; 62(9):1592-6. PubMed ID: 25820920
    [Abstract] [Full Text] [Related]

  • 9. Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion.
    Kattamis A, Kassou C, Berdousi H, Ladis V, Papassotiriou I, Kattamis C.
    Haematologica; 2003 Dec 21; 88(12):1423-5. PubMed ID: 14687998
    [No Abstract] [Full Text] [Related]

  • 10. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
    Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Roughton M, Assomull R, Nair SV, Walker JM, Pennell DJ.
    Circulation; 2007 Apr 10; 115(14):1876-84. PubMed ID: 17372174
    [Abstract] [Full Text] [Related]

  • 11. Combined therapy with deferiprone and desferrioxamine in thalassemia major.
    Origa R, Bina P, Agus A, Crobu G, Defraia E, Dessì C, Leoni G, Muroni PP, Galanello R.
    Haematologica; 2005 Oct 10; 90(10):1309-14. PubMed ID: 16219566
    [Abstract] [Full Text] [Related]

  • 12. Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients.
    Hoffbrand AV, AL-Refaie F, Davis B, Siritanakatkul N, Jackson BF, Cochrane J, Prescott E, Wonke B.
    Blood; 1998 Jan 01; 91(1):295-300. PubMed ID: 9414297
    [Abstract] [Full Text] [Related]

  • 13. A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong.
    Ha SY, Chik KW, Ling SC, Lee AC, Luk CW, Lam CW, Ng IO, Chan GC.
    Hemoglobin; 2006 Jan 01; 30(2):263-74. PubMed ID: 16798652
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major.
    Farmaki K, Tzoumari I, Pappa C, Chouliaras G, Berdoukas V.
    Br J Haematol; 2010 Feb 01; 148(3):466-75. PubMed ID: 19912219
    [Abstract] [Full Text] [Related]

  • 16. Longitudinal prospective comparison of pancreatic iron by magnetic resonance in thalassemia patients transfusion-dependent since early childhood treated with combination deferiprone-desferrioxamine vs deferiprone or deferasirox monotherapy.
    Ricchi P, Meloni A, Pistoia L, Gamberini MR, Cuccia L, Allò M, Putti MC, Spasiano A, Rosso R, Cecinati V, Righi R, Renne S, Peritore G, Vallone A, Positano V, Quaia E, Cademartiri F, Pepe A.
    Blood Transfus; 2024 Jan 01; 22(1):75-85. PubMed ID: 37146300
    [Abstract] [Full Text] [Related]

  • 17. The effect of combined therapy with deferoxamine and deferiprone on serum ferritin level of beta-thalassemic patients.
    Mirbehbahani N, Jahazi A, Rahim Abad HH.
    Hematology; 2012 May 01; 17(3):183-6. PubMed ID: 22664119
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and Safety of Combined Oral Chelation With Deferiprone and Deferasirox in Children With β-Thalassemia Major: An Experience From North India.
    Parakh N, Chandra J, Sharma S, Dhingra B, Jain R, Mahto D.
    J Pediatr Hematol Oncol; 2017 Apr 01; 39(3):209-213. PubMed ID: 28221264
    [Abstract] [Full Text] [Related]

  • 19. Iron chelation therapy.
    Hoffbrand AV, Wonke B.
    J Intern Med Suppl; 1997 Apr 01; 740():37-41. PubMed ID: 9350180
    [Abstract] [Full Text] [Related]

  • 20. Safety monitoring of cardiac and hepatic systems in beta-thalassemia patients with chelating treatment in Taiwan.
    Peng CT, Chow KC, Chen JH, Chiang YP, Lin TY, Tsai CH.
    Eur J Haematol; 2003 Jun 01; 70(6):392-7. PubMed ID: 12756022
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.